| Name | Colistin sulfate |
| Description | Colistin sulfate (Colistin sulfate (1066-17-7 free base)) is a cyclic polypeptide antibiotic from Bacillus colistinus, composed of Polymyxins E1 and E2. |
| In vitro | In mice, daily intramuscular injections of Colistin sulfate (15 mg/kg) result in granular degeneration in renal and hepatic epithelial tissues. Similarly, in piglets, daily intramuscular injections of Colistin sulfate (15 mg/kg) lead to significant neurotoxic effects. |
| In vivo | Colistin (2 μg/mL) exhibits broad-spectrum antibacterial activity, effectively inhibiting most strains of Escherichia coli and Pseudomonas aeruginosa, as well as all strains of the genera Enterobacter, Salmonella, Shigella, Pasteurella, Brucella, and Bordetella. Additionally, it is active against strains of the genera Moraxella, Serratia, and Providencia. In 225 strains of P. aeruginosa, the MIC90 and MIC50 of Colistin are 6.3 μg/mL and 1.6 μg/mL, respectively. In Acinetobacter baumannii, Colistin sulfate demonstrates concentration-dependent post-antibiotic effects. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 10 mM
DMSO : Insoluble
|
| Keywords | Colistin sulfate | Polymyxin E | Autophagy | 1066-17-7 free base | Antibiotic | inhibit | Colistin | Colistin Sulfate | Inhibitor | Bacterial | 1066-17-7 |
| Related Compound Libraries | Bioactive Compound Library | Cyclic Peptide Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Microbial Natural Product Library | Natural Product Library for HTS | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
